• FirefoxInstall the new Firefox »
  •  Dow Down0.06% Nasdaq Up0.42%

    Imprimis Pharmaceuticals, Inc. (IMMY)

    -NasdaqCM
    7.77 Up 0.11(1.46%) Feb 26, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Imprimis Pharmaceuticals, Inc.
    12626 High Bluff Drive
    Suite 150
    San Diego, CA 92130
    United States - Map
    Phone: 858-704-4040
    Fax: 858-345-1745
    Website: http://www.imprimispharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:17

    Business Summary 

    Imprimis Pharmaceuticals, Inc. operates as a specialty pharmaceutical company focusing on the commercial development of compounded drug formulations. The company, through a strategic relationship with Professional Compounding Centers of America, Inc., expects to use its proprietary Accudel drug delivery technology, coupled with licensed technologies, and proprietary formulations and market data, to facilitate its future selection, formulation, and development of potential product candidates. The company is also internally developing non-invasive, topically delivered products. Its patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. The company’s lead Phase III pain product candidate, Impracor, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. It intends to leverage the Accudel platform technology to expand and create a portfolio of topical products for various indications. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Imprimis Pharmaceuticals, Inc.

    Key Executives 
     PayExercised
    Mr. Mark L. Baum Esq., J.D., 42
    Founder, Chief Exec. Officer and Director
    421.00K0.00
    Mr. Andrew R. Boll CMA, 33
    Chief Financial Officer
    185.00K0.00
    Mr. Joe Bitterman R.Ph.,
    Sr. Operations Director
    N/AN/A
    Mr. Gary W. Seelhorst MS, MBA, 44
    Vice-Pres of Corp. Devel.
    N/AN/A
    Mr. John Saharek ,
    Chief Commercial Officer
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders